logo
Falcons in new naming rights deal for Joondalup home ground

Falcons in new naming rights deal for Joondalup home ground

Perth Now23-04-2025
West Perth have signed a new sponsorship deal at its Joondalup venue.
The Falcons' home ground will be known as HIF Health Insurance Oval in a three-year deal, which will include HIF-sponsored games and fan days.
HIF chief executive Glenn Oellermann said West Perth was quintessentially West Australian as the oldest WA Football League club.
Your local paper, whenever you want it.
'As a proud not-for-profit West Australian-based health fund serving the community for over 70 years, we see a strong alignment in partnering with the club,' he said.
'Our shared values on health, wellness and the importance of community in WA are further highlighted by the importance of supporting grassroots football in our home state.
'It's exciting to see the Falcons perform on the field this 2025 season.'
West Perth chief executive Joe McCarthy said as proud advocates around the importance of sport in the community, 'our values align perfectly with those that are displayed at HIF'.
'This three-year partnership not only gives our club financial sustainability, it also allows us to grow additional areas within health and wellbeing.
'Our unique game day proposals of both night and twilight football will showcase HIF Health Insurance Oval to all and we encourage all Falcons fans to come down and enjoy the atmosphere.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The start-up making drugs in space, then sending them to Australia at 30,870km/h
The start-up making drugs in space, then sending them to Australia at 30,870km/h

The Age

time7 hours ago

  • The Age

The start-up making drugs in space, then sending them to Australia at 30,870km/h

When it comes to the future, you have to ask: are we there yet? For example, is it possible that space capsules are orbiting the Earth – while they make advanced drug compounds? And then the same capsules are returning to terra firma after travelling at 25 times the speed of sound into our atmosphere? Why, yes ... And when they return to Earth, they are returning to Australia? Yes, again. 'It's actually much less futuristic than it sounds,' says Will Bruey, CEO of Varda Industries, the company launching the drug-factory capsules. 'On average three SpaceX Starlink satellites are launched per day, and our spacecraft is simpler, quite frankly, than a Starlink satellite,' he says. And, while it's early days for California-based Varda, founded in 2021, the pace of launch for these capsules – whose journey takes them from the US, to low earth orbit, to a South Australian testing range for recovery – is expected to increase. The start-up is attempting to create a viable business of manufacturing drugs in space, where the lack of gravity unlocks the possibility of new, more effective – and more profitable – drug compounds that can't be made on Earth. Being in space, the limits on the scale of manufacturing are different to an Earth-bound enterprise – both in the molecular quality of what can be produced and, potentially one day, the scale of the production facility. For now, the company's future depends on how effectively and profitably it can formulate drugs – or at least the most effective primary active pharmaceutical ingredient – in orbit. When discussing drug production, Bruey compares microgravity (ultra-low gravity in orbit) to the effect that refrigeration has had on drug production since it was invented. Before refrigeration existed, people would have asked, how could it create value for pharmaceuticals? Today, refrigeration is a fundamental part of drug and vaccine manufacturing, shipping and storage. It reduces the risk of contamination and helps ensure the drugs are effective. Profitable drug manufacturing would be almost unthinkable without it. One day, space-based drugs may be discussed the same way. 'The way the pharmaceutical industry will think about [Varda] shortly is just another piece of equipment.' Even the name of the spacecraft – the W in Varda's W-series capsule – unofficially stands for 'Winnebago' (or caravan in American English) used in TV series Breaking Bad, which is itself a story about the remote, compartmentalised cooking up of drugs. 'Instead of going to the desert, we're going to space,' Bruey said. Likewise, Varda is hauling its equipment to a destination to make its batch, then coming back. 'So that's what we'll be doing. And we'll just be increasing the amount of Winnebagos that are going out to space and back.' 'There's a lot of low-hanging fruit and optimisation to be done in that paradigm.' Any drug with a formulation improvement worth more than $US200 a gram is viable for Varda to manufacture today. But Varda forecasts it can drive down the cost from $US200 to $US20 'pretty easily by just making our systems more reusable'. To push lower than that, the company will construct a permanent station with manufacturing equipment that can be used for multiple drugs, Bruey says. Much of the science around drugmaking in space has been done. There have been numerous experiments on pharmaceuticals, for example, on the International Space Station. Varda hopes to have a space-made drug in humans by the end of the decade. In an era of sagging productivity, it's worth considering the value of genre-melding new ventures. The question is: how much demand is there for a service that is new to the world? And on Earth – in Australia – how many re-entries could we see? Adelaide-based company, Southern Launch, was formed in 2017 as a spaceport operator providing launch services. It has since begun offering orbital re-entry services for customers like Varda. Their range, at Koonibba in South Australia, enjoys clearer skies with less air traffic than test ranges in the US, giving more flexibility to Varda and other clients, Southern Launch says. Southern Launch CEO Lloyd Damp said the missions conducted for Varda so far, 'mark an incredible step forward for Australia as the global landing site for re-entries and the in-space manufactured goods the capsules carry.' Investing in an unproven business model is riskier than investing in say, inner city residential property. But Bruey sees Varda as carving out a niche that can expand as demand grows. 'Basically, there's only four fundamental forces of physics, and gravity is one of them, and we have a knob on [it], and no other company does.' (If you're wondering, the three other forces are: electromagnetism and the strong and weak nuclear forces). Bruey knows about physics because he studied the subject at Cornell University before founding a couple of companies and working at Elon Musk's SpaceX. Bruey then met up with Delian Asparouhov, who was looking to invest in a company that could do this work. Asparouhov was looking for someone with Bruey's background and who 'was willing to drop everything and go on this adventure'. Varda now has backing from Khosla Ventures, Lux Capital, Caffeinated Capital, Founders Fund, and General Catalyst. It has raised $US187 million in a new funding round this month, bringing the total capital raised to $US329 million. The bet that money can be made by low-orbit manufacturing has caught the attention of SpaceX, which reportedly has plans to get into the space-drug game by manufacturing too. Elon Musk's company plans to use its massive – and recently unlucky – Starship rocket for the purpose, according to Bloomberg. Sources close to Varda call the report about SpaceX's plan, called Starfall, a 'validation' of Varda's business model. Like SpaceX, Varda's goal isn't science, it's business: advanced, space-tech business, with the potential to unlock a huge new market that could one day involve large in-orbit factories. The in-space manufacturing market could be worth $US10 billion in five years, according to McKinsey. But exploiting a fundamental force of physics for profit comes with some hard realities. If you send the capsule into space, you must find a reliable place to recover the spacecraft – closing the loop on the production process. That's where Australia comes in. Varda's first craft W-1, launched in June 2023, was due to return in July, but instead got delayed as the company sought permission for the landing in Utah. It remained in orbit for eight months while the details of a new license were resolved between government authorities. While W-1 was in orbit, Varda reached out to Australia's space industry, looking for reliable space return services. W-1's February 2024 return coincided with Varda being granted a 'Part 450 re-entry license' from the FAA's Office of Space Transportation, part of a new process to accommodate repeated missions common in commercial space. Varda now has a FAA license which allows the company to launch and re-enter a craft without spelling out the identical parameters of the mission on repeated applications. When Varda's W-2 landed in South Australia, Enrico Palermo, head of the Australian Space Agency said it highlighted 'the opportunity for Australia to become a responsible launch and return hub for the global space community, capitalising off the geographic advantages of our expansive continent.' Unlike crewed missions, which must gently skim into the atmosphere without burning up to bring humans safely home, Varda's missions comes in 'ballistically, as if it's like a missile'. In that phase, the Winnebagos achieve Mach 25, twenty-five times the speed of sound, or 30,870 kilometres per hour. Varda has attached a camera to the capsule to capture the dramatic re-entry footage, which looks something like a gas log on overdrive. In space. The pink glow you see is plasma, Bruey says, from the capsule moving so fast and creating so much heat 'it's literally ripping the molecules in the atmosphere apart and ripping away their electrons'. 'The streaks of what looks like fire is the heat shield 'ablating', that is the little pieces coming off intentionally to take away the heat, shedding it from the spacecraft.' So far, Varda has created a crystal form of an HIV drug ritonavir in space. It has research collaborations with large pharma brands, whose names Varda would not give, citing non-disclosure agreements. W-2 and W-3 landed in February and May 2025 at Koonibba Test Range in South Australia. W-4 is currently in orbit. Varda says it is on track for four missions in 2025 – with plans to expand to a double-capsule mission in 2026. From there, the pace is expected to increase to a weekly pace. Veteran space industry observer and contributor Brett Biddington says Australia is 'well-suited to support the recovery of payloads from space' with a historical record that is 'unblemished'. 'Whether a viable business can be made just from recovery support is another question,' he says. He expects that the 'activity will be lumpy and sporadic' and can best thought of as a 'supplementary income stream' to one that is more reliable. Varda's plan isn't to create a new business alone, but the industry needed to support and grow the enterprise. With the capsules going up and coming back, we will soon know if Varda is successful.

Kembla Grange stables unveil pair of exciting fillies at Moruya
Kembla Grange stables unveil pair of exciting fillies at Moruya

Sydney Morning Herald

time7 hours ago

  • Sydney Morning Herald

Kembla Grange stables unveil pair of exciting fillies at Moruya

A pair of Kembla-based two-year-old fillies, both on debut, can steal the show when they travel south to tackle the older horses at Monday's Moruya meeting. Spice Baby, an exciting daughter of 2018 Golden Gift winner Tassort in the Joseph Isle stable and drawn the inside, is likely to jump favourite in a Maiden Handicap over 1020m. But drawn just two places further out, the Kerry Parker yard unveils Miss Steffi, a well-bred and aptly named daughter of Group 2-winning Graff. Spice Baby has been strong through the line in two lead-up trials and draws to get a cosy run, while Miss Steffi also starts behind two recent trials, winning the first at home before given a quieter time at Rosehill only six days ago. Named after the tennis great, Miss Steffi is bred to get much further being out of a Carnegie mare, and will be aimed at some feature middle-distance affairs in early spring if she heads in the right direction. Spice Baby, out of a mare by 2005 Golden Slipper winner Stratum and to be ridden by Louise Day, is more the sprinting type and opened about $3.70 in early betting alongside Canberra-based Caravanserai, an ex-Godolphin three-year-old having his first run in six months for the new Natalie Jarvis stable. Miss Steffi, to be ridden by Adrian Layt, was further out about the $7 mark. Meanwhile, the far-reaching success of Canberra stables is set to continue, headed by the Matthew Kelley yard which heads to the South Coast eyeing off a double. Loading

Tips and race-by-race guide for Moruya on Monday
Tips and race-by-race guide for Moruya on Monday

The Age

time7 hours ago

  • The Age

Tips and race-by-race guide for Moruya on Monday

How to play it: Think I Do to win. Race 4 9. Beauty Dash is an emerging mare which can break through at her fourth start. Will probably be forced a long way back from the wide barrier, but she's run home late into a place in her last couple, and should get more speed on here to allow her to work into the race a little earlier. 13. Wolf Island is a Canberra two-year-old resuming as a gelding for his second start, so the market will be a big indicator. 3. Brannum is also a market watch resuming for his third start from a low draw for another leading country stable. 6. McTominay is in the mix at his fifth start, having beaten all bar the winner in his last two, and gets some weight relief. 7. Shoreman is over the odds fourth-up getting back on turf. How to play it: Beauty Dash to win. Race 5 10. Miss Steffi is a Kembla-based and well-named two-year-old filly by Graff having her first start behind two trials. Will be better over further, but from an ideal draw where she can be tucked away with cover, only needs a clear crack at them over the final 300m. Over the odds for a very shrewd stable. 11. Spice Baby is another juvenile filly from Kembla on debut which draws the fence and has been fitted with two solid and recent trials. 1. Caravanserai is an ex-Godolphin three-year-old having his first run for the new Canberra stable off a six-month spell. Lightly raced and drawn wide, but has ability. 6. Molteuno can improve sharply at her second outing from a softer draw. 9. Brutal Belle can run into the minor money second-up. Gap to the rest. How to play it: Miss Steffi to win. Race 6 6. Getty is another one from Canberra primed to strike fresh for the in-form Matthew Kelley stable in another very open race. Can use his tactical speed from a low draw and comes to hand quickly. Handles all going. 3. Scissor Me Timbers, a capable and locally trained four-year-old, will be hard to hold out second-up with the blinkers added after doing his best work late here in a deeper BM 66 10 days ago. 1. Perigean is over the odds second-up with a gear change and coming back from that same race as the former. Keep safe 8. Rippana despite a class rise second-up, with a serious drop in weight after the claim. 4. Acheson, dropping back from a much tougher Class 3 Highway at Randwick, can figure in the minor money; while 5. Ditterich, down in weight second-up adds value into trifecta and first-four plays. How to play it: Getty to win. Race 7 6. Teepee Princess is a home-track filly primed to make it two straight to start her career reloading from an upset maiden win at at big odds. Market got it wrong last time, and given she's bred to get much further, only needs a fair run from a middle gate to finish stronger again. 3. Dame Annie is a progressive metropolitan mare coming off first-up win in heavy going against weaker opposition. 2. Lady Revolution is a betting watch first-up for four months behind a quiet trial. 5. Gooloo Bucky is progressive enough coming off a dominant second-up maiden win at this track 10 days ago. 4. Deni Gal is each-way value back in grade from the inside draw. How to play it: Teepee Princess to win. Race 8 3. Dolzino is a locally trained and improving four-year-old which shapes ideally third-up coming back from a much tougher Class 3 Highway at Rosehill, where he made up late ground. Settles closer in the run over more ground and from a more economical draw. Only needs a clear look at them from the top of the straight to claim a second career win. 2. Fire And Gemstone is over the mark from a handy draw after missing by under a length third-up here 24 days ago when freshened. 6. Thoughtful can run into the minor money third-up with the blinkers removed; while 9. Crazy Atom improves with blinkers going on.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store